Hunan Hansen Pharmaceutical Hits Day Low Amid Price Pressure, Drops to CNY 6.04

Hunan Hansen Pharmaceutical Co. experienced significant activity on March 23, 2026, with the stock declining by 7.75% and reaching an intraday low of CNY 6.04. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% on the same day. Over the past week, Hunan Hansen has seen a decline of 13.16%, while its one-month performance shows a drop of 18.08%. Year-to-date, the stock has decreased by 5.3%, underperforming the market, which has seen a decline of 3.92%. In the last year, Hunan Hansen's return of 5.11% is notably lower than the China Shanghai Composite's return of 16.08%. Financial metrics indicate challenges for the company, with a net profit of CNY 13.52 million reflecting a significant decrease of 70.99%. The operating cash flow is reported at CNY 171.58 million, marking a low point for the company. Additionally, the interest coverage ratio stands at 9,139.09, indicating a cautious financial position. Hunan Hansen's market capitalization is CNY 3,626 million, categorizing it as a small-cap company in the pharmaceuticals and biotechnology sector.